The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women

Jack D. Sobel, Suzanne E. Ohmit, Paula Schuman, Robert S. Klein, Kenneth Mayer, Ann Duerr, Jose A. Vazquez, Anne Rompalo, Robert S. Klein, Ellie Schoenbaum, Robert D. Burk, Julia H. Arnsten, Chee Jen Chang, Penelope Demas, Andrea Howard, Paula Schuman, Jack D. Sobel, Suzanne E. Ohmit, William Brown, Wayne LancasterAnne Rompalo, Keerti Shaw, David Vlahov, David Celantano, Kenneth Mayer, Susan Cu-Uvin, Timothy Flanigan, Joseph Hogan, Valerie Stone, Karen Tashima, Josiah Rich, Ann Duerr, Lytt Gardner, Dora Warren, Denise Jamieson, Jan Moore, Dawn Smith, Scott Holmberg, Ruby Phelps, Chad Heilig, Katherine Davenny

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Antifungal agents can effectively treat mucosal candidiasis; however, their use can lead to colonization with less susceptible species and to resistance among normally susceptible strains. Oral and vaginal Candida isolates obtained at 3 points over 2 years from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women were identified by species and were evaluated for in vitro fluconazole susceptibility. Prevalence of non-C. albicans strains increased over time, and these strains were more likely among women reporting current antifungal use. Among C. albicans isolates, resistance was rare, with no evidence for progressive reduction in susceptibility over time. Among non-C. albicans isolates, reduced susceptibility occurred frequently and increased with time. HIV-seropositive women were more likely to have non-C. albicans isolates with reduced susceptibility as were women reporting current antifungal use. This evolution and selection of mucosa-colonizing Candida species with reduced susceptibility could play a critical early role in the development of antifungal resistance among C. albicans isolates responsible for refractory candidiasis.

Original languageEnglish (US)
Pages (from-to)286-293
Number of pages8
JournalJournal of Infectious Diseases
Volume183
Issue number2
DOIs
StatePublished - Jan 15 2001

Fingerprint

Fluconazole
Candida
HIV
Candidiasis
HIV-2
Antifungal Agents
Mucous Membrane

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. / Sobel, Jack D.; Ohmit, Suzanne E.; Schuman, Paula; Klein, Robert S.; Mayer, Kenneth; Duerr, Ann; Vazquez, Jose A.; Rompalo, Anne; Klein, Robert S.; Schoenbaum, Ellie; Burk, Robert D.; Arnsten, Julia H.; Chang, Chee Jen; Demas, Penelope; Howard, Andrea; Schuman, Paula; Sobel, Jack D.; Ohmit, Suzanne E.; Brown, William; Lancaster, Wayne; Rompalo, Anne; Shaw, Keerti; Vlahov, David; Celantano, David; Mayer, Kenneth; Cu-Uvin, Susan; Flanigan, Timothy; Hogan, Joseph; Stone, Valerie; Tashima, Karen; Rich, Josiah; Duerr, Ann; Gardner, Lytt; Warren, Dora; Jamieson, Denise; Moore, Jan; Smith, Dawn; Holmberg, Scott; Phelps, Ruby; Heilig, Chad; Davenny, Katherine.

In: Journal of Infectious Diseases, Vol. 183, No. 2, 15.01.2001, p. 286-293.

Research output: Contribution to journalArticle

Sobel, JD, Ohmit, SE, Schuman, P, Klein, RS, Mayer, K, Duerr, A, Vazquez, JA, Rompalo, A, Klein, RS, Schoenbaum, E, Burk, RD, Arnsten, JH, Chang, CJ, Demas, P, Howard, A, Schuman, P, Sobel, JD, Ohmit, SE, Brown, W, Lancaster, W, Rompalo, A, Shaw, K, Vlahov, D, Celantano, D, Mayer, K, Cu-Uvin, S, Flanigan, T, Hogan, J, Stone, V, Tashima, K, Rich, J, Duerr, A, Gardner, L, Warren, D, Jamieson, D, Moore, J, Smith, D, Holmberg, S, Phelps, R, Heilig, C & Davenny, K 2001, 'The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women', Journal of Infectious Diseases, vol. 183, no. 2, pp. 286-293. https://doi.org/10.1086/317936
Sobel, Jack D. ; Ohmit, Suzanne E. ; Schuman, Paula ; Klein, Robert S. ; Mayer, Kenneth ; Duerr, Ann ; Vazquez, Jose A. ; Rompalo, Anne ; Klein, Robert S. ; Schoenbaum, Ellie ; Burk, Robert D. ; Arnsten, Julia H. ; Chang, Chee Jen ; Demas, Penelope ; Howard, Andrea ; Schuman, Paula ; Sobel, Jack D. ; Ohmit, Suzanne E. ; Brown, William ; Lancaster, Wayne ; Rompalo, Anne ; Shaw, Keerti ; Vlahov, David ; Celantano, David ; Mayer, Kenneth ; Cu-Uvin, Susan ; Flanigan, Timothy ; Hogan, Joseph ; Stone, Valerie ; Tashima, Karen ; Rich, Josiah ; Duerr, Ann ; Gardner, Lytt ; Warren, Dora ; Jamieson, Denise ; Moore, Jan ; Smith, Dawn ; Holmberg, Scott ; Phelps, Ruby ; Heilig, Chad ; Davenny, Katherine. / The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. In: Journal of Infectious Diseases. 2001 ; Vol. 183, No. 2. pp. 286-293.
@article{373186c1fb984d71b70626f9ebd76f6b,
title = "The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women",
abstract = "Antifungal agents can effectively treat mucosal candidiasis; however, their use can lead to colonization with less susceptible species and to resistance among normally susceptible strains. Oral and vaginal Candida isolates obtained at 3 points over 2 years from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women were identified by species and were evaluated for in vitro fluconazole susceptibility. Prevalence of non-C. albicans strains increased over time, and these strains were more likely among women reporting current antifungal use. Among C. albicans isolates, resistance was rare, with no evidence for progressive reduction in susceptibility over time. Among non-C. albicans isolates, reduced susceptibility occurred frequently and increased with time. HIV-seropositive women were more likely to have non-C. albicans isolates with reduced susceptibility as were women reporting current antifungal use. This evolution and selection of mucosa-colonizing Candida species with reduced susceptibility could play a critical early role in the development of antifungal resistance among C. albicans isolates responsible for refractory candidiasis.",
author = "Sobel, {Jack D.} and Ohmit, {Suzanne E.} and Paula Schuman and Klein, {Robert S.} and Kenneth Mayer and Ann Duerr and Vazquez, {Jose A.} and Anne Rompalo and Klein, {Robert S.} and Ellie Schoenbaum and Burk, {Robert D.} and Arnsten, {Julia H.} and Chang, {Chee Jen} and Penelope Demas and Andrea Howard and Paula Schuman and Sobel, {Jack D.} and Ohmit, {Suzanne E.} and William Brown and Wayne Lancaster and Anne Rompalo and Keerti Shaw and David Vlahov and David Celantano and Kenneth Mayer and Susan Cu-Uvin and Timothy Flanigan and Joseph Hogan and Valerie Stone and Karen Tashima and Josiah Rich and Ann Duerr and Lytt Gardner and Dora Warren and Denise Jamieson and Jan Moore and Dawn Smith and Scott Holmberg and Ruby Phelps and Chad Heilig and Katherine Davenny",
year = "2001",
month = "1",
day = "15",
doi = "10.1086/317936",
language = "English (US)",
volume = "183",
pages = "286--293",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women

AU - Sobel, Jack D.

AU - Ohmit, Suzanne E.

AU - Schuman, Paula

AU - Klein, Robert S.

AU - Mayer, Kenneth

AU - Duerr, Ann

AU - Vazquez, Jose A.

AU - Rompalo, Anne

AU - Klein, Robert S.

AU - Schoenbaum, Ellie

AU - Burk, Robert D.

AU - Arnsten, Julia H.

AU - Chang, Chee Jen

AU - Demas, Penelope

AU - Howard, Andrea

AU - Schuman, Paula

AU - Sobel, Jack D.

AU - Ohmit, Suzanne E.

AU - Brown, William

AU - Lancaster, Wayne

AU - Rompalo, Anne

AU - Shaw, Keerti

AU - Vlahov, David

AU - Celantano, David

AU - Mayer, Kenneth

AU - Cu-Uvin, Susan

AU - Flanigan, Timothy

AU - Hogan, Joseph

AU - Stone, Valerie

AU - Tashima, Karen

AU - Rich, Josiah

AU - Duerr, Ann

AU - Gardner, Lytt

AU - Warren, Dora

AU - Jamieson, Denise

AU - Moore, Jan

AU - Smith, Dawn

AU - Holmberg, Scott

AU - Phelps, Ruby

AU - Heilig, Chad

AU - Davenny, Katherine

PY - 2001/1/15

Y1 - 2001/1/15

N2 - Antifungal agents can effectively treat mucosal candidiasis; however, their use can lead to colonization with less susceptible species and to resistance among normally susceptible strains. Oral and vaginal Candida isolates obtained at 3 points over 2 years from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women were identified by species and were evaluated for in vitro fluconazole susceptibility. Prevalence of non-C. albicans strains increased over time, and these strains were more likely among women reporting current antifungal use. Among C. albicans isolates, resistance was rare, with no evidence for progressive reduction in susceptibility over time. Among non-C. albicans isolates, reduced susceptibility occurred frequently and increased with time. HIV-seropositive women were more likely to have non-C. albicans isolates with reduced susceptibility as were women reporting current antifungal use. This evolution and selection of mucosa-colonizing Candida species with reduced susceptibility could play a critical early role in the development of antifungal resistance among C. albicans isolates responsible for refractory candidiasis.

AB - Antifungal agents can effectively treat mucosal candidiasis; however, their use can lead to colonization with less susceptible species and to resistance among normally susceptible strains. Oral and vaginal Candida isolates obtained at 3 points over 2 years from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women were identified by species and were evaluated for in vitro fluconazole susceptibility. Prevalence of non-C. albicans strains increased over time, and these strains were more likely among women reporting current antifungal use. Among C. albicans isolates, resistance was rare, with no evidence for progressive reduction in susceptibility over time. Among non-C. albicans isolates, reduced susceptibility occurred frequently and increased with time. HIV-seropositive women were more likely to have non-C. albicans isolates with reduced susceptibility as were women reporting current antifungal use. This evolution and selection of mucosa-colonizing Candida species with reduced susceptibility could play a critical early role in the development of antifungal resistance among C. albicans isolates responsible for refractory candidiasis.

UR - http://www.scopus.com/inward/record.url?scp=0035863545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035863545&partnerID=8YFLogxK

U2 - 10.1086/317936

DO - 10.1086/317936

M3 - Article

C2 - 11204125

AN - SCOPUS:0035863545

VL - 183

SP - 286

EP - 293

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -